Indication
Idiopathic Short Stature
5 clinical trials
7 products
2 drugs
Clinical trial
A Multicenter, Randomized, Open-label, Positive-controlled Phase 2 Study to Explore the Optimal Dose of Y- Shaped Pegylated Recombinant Growth Hormone (YPEG-rhGH) in Children With Short Stature (ISS, SGA, TS)Status: Completed, Estimated PCD: 2023-10-23
Product
YPEG-rhGHProduct
rhGHClinical trial
Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height.Status: Active (not recruiting), Estimated PCD: 2024-01-01
Product
somatropinDrug
triptorelinClinical trial
Recombinant Human Growth Hormone (GH): Effects on Metabolic Profile, Body Composition and Skeletal Muscle Strength and Function in Pre-pubertal Short Boys With and Without GH DeficiencyStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Product
SomatropinClinical trial
A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short StatureStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Product
VosoritideProduct
Human Growth HormoneDrug
VarlilumabClinical trial
Pilot Study of Ethiology Research by a Multidisciplinary Evaluation Then a Genome-wide Analysis in a Cohort of Idiopathic Short Stature PatientsStatus: Not yet recruiting, Estimated PCD: 2026-06-01